|
|
|
|
|
| Angelucci,M.E.M.; Cesário,C.; Hiroi,R.H.; Rosalen,P.L.; Cunha,C. Da. |
| We studied some of the characteristics of the improving effect of the non-specific adenosine receptor antagonist, caffeine, using an animal model of learning and memory. Groups of 12 adult male Wistar rats receiving caffeine (0.3-30 mg/kg, ip, in 0.1 ml/100 g body weight) administered 30 min before training, immediately after training, or 30 min before the test session were tested in the spatial version of the Morris water maze task. Post-training administration of caffeine improved memory retention at the doses of 0.3-10 mg/kg (the rats swam up to 600 cm less to find the platform in the test session, P<=0.05) but not at the dose of 30 mg/kg. Pre-test caffeine administration also caused a small increase in memory retrieval (the escape path of the rats... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Memory; Learning; Caffeine; Methylxanthines; Adenosine receptor antagonist; Morris water maze. |
| Ano: 2002 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2002001000013 |
| |
|
|
| Ferro,M.M.; Angelucci,M.E.M.; Anselmo-Franci,J.A.; Canteras,N.S.; Da Cunha,C.. |
| There is a great concern in the literature for the development of neuroprotectant drugs to treat Parkinson's disease. Since anesthetic drugs have hyperpolarizing properties, they can possibly act as neuroprotectants. In the present study, we have investigated the neuroprotective effect of a mixture of ketamine (85 mg/kg) and xylazine (3 mg/kg) (K/X) on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or 6-hydroxydopamine (6-OHDA) rat models of Parkinson's disease. The bilateral infusion of MPTP (100 µg/side) or 6-OHDA (10 µg/side) into the substantia nigra pars compacta of adult male Wistar rats under thiopental anesthesia caused a modest (~67%) or severe (~91%) loss of tyrosine hydroxylase-immunostained cells, respectively. On the other hand, an... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Neuroprotection 6-Hydroxydopamine 1-Methyl-4-phenyl-1; 2; 3; 6- tetrahydropyridine Ketamine Parkinson's disease. |
| Ano: 2007 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007000100012 |
| |
|
|
|
